Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

[1]  K. Hoang-Xuan,et al.  Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS) , 2016 .

[2]  T. Batchelor.  Primary central nervous system lymphoma. , 2016, Hematology. American Society of Hematology. Education Program.

[3]  M. Pfreundschuh,et al.  High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. , 2016, The Lancet. Haematology.

[4]  R. Pfeiffer,et al.  Trends in primary central nervous system lymphoma incidence and survival in the U.S. , 2016, British journal of haematology.

[5]  F. Cavalli,et al.  Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. , 2016, The Lancet. Haematology.

[6]  A. Ferreri,et al.  The role of autologous stem cell transplantation in primary central nervous system lymphoma. , 2016, Blood.

[7]  T. Fischer,et al.  Characteristics and outcome of patients with primary CNS lymphoma in a “real-life” setting compared to a clinical trial , 2016, Annals of Hematology.

[8]  D. Correa,et al.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. , 2015, Blood.

[9]  J. Finke,et al.  Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  D. Correa,et al.  Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Maron,et al.  Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma , 2013, Neurology.

[12]  B. Cheson,et al.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Duggan,et al.  Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience , 2012, Leukemia & lymphoma.

[14]  D. Correa,et al.  Cognitive functions in primary CNS lymphoma after single or combined modality regimens. , 2012, Neuro-oncology.

[15]  M. Reni,et al.  Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. , 2011, International journal of radiation oncology, biology, physics.

[16]  L. Deangelis.  Radiotherapy: Has the role of WBRT in primary CNS lymphoma been settled? , 2011, Nature Reviews Clinical Oncology.

[17]  B. O'neill,et al.  Whole-brain radiotherapy in primary CNS lymphoma. , 2011, The Lancet. Oncology.

[18]  E. Thiel,et al.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.

[19]  F. Cavalli,et al.  Flows and flaws in primary central nervous system lymphoma , 2010, Nature Reviews Clinical Oncology.

[20]  F. Cavalli,et al.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial , 2009, The Lancet.

[21]  F. Feuerhake,et al.  High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system , 2008, Haematologica.

[22]  D. Correa,et al.  Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Niederwieser,et al.  Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Bay,et al.  High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group , 2006, Bone Marrow Transplantation.

[26]  F. Feuerhake,et al.  High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Armitage,et al.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Zelenetz,et al.  Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[30]  J. Blay,et al.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Deangelis,et al.  Primary CNS lymphoma , 2002, Neurology.

[32]  J. Blay,et al.  A multicenter study of treatment of primary CNS lymphoma , 2002, Neurology.

[33]  J. Blay,et al.  Relevance of intraocular involvement in the management of primary central nervous system lymphomas. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  B. Smith,et al.  Pharmacology of agents used in bone marrow transplant conditioning regimens. , 1992, Critical reviews in oncology/hematology.